Redeye provides a short comment on Fluoguide’s Q4 earnings and the company's outlook for 2026. The report contained no major surprises, which is typical for a pre-revenue biotech company. Importantly, Fluoguide leaves behind a prosperous 2025, marked by a successful share issue, continued clinical progress and key regulatory advancements that have laid a strong foundation for the company’s next phase of development. As a result, 2026 is shaping up to be a pivotal year, with the initiation of a Phase II study of FG001 in high-grade glioma (HGG) representing a major milestone. In addition, several further clinical catalysts are expected throughout the year, supporting continued momentum in the FG001 programme.
LÄS MER
